help button home button Am J Pathol Epitomics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/ajpath.2010.090447 on January 7, 2010

Published online before print January 7, 2010
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ajpath.2010.090447v1
176/2/650    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Zhu, F.
Right arrow Articles by Yu, X.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, F.
Right arrow Articles by Yu, X.
(American Journal of Pathology. 2010;176:650-659.)
© 2010 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2010.090447

Preventive Effect of Notch Signaling Inhibition by a {gamma}-Secretase Inhibitor on Peritoneal Dialysis Fluid-Induced Peritoneal Fibrosis in Rats

Fengxin Zhu*, Tang Li*, Fanghua Qiu{dagger}, Jinjin Fan*, Qin Zhou*, Xuebing Ding*, Jing Nie* and Xueqing Yu*

From the Department of Nephrology,* The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; and the Laboratory of Proteomics,{dagger} The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Peritoneal fibrosis, a major complication of peritoneal dialysis, limits the effectiveness of peritoneal dialysis as a treatment of end-stage renal disease. Preventing this complication by identifying targets for therapy has recently received much attention. In the present study, we showed that Notch signaling was highly activated in rats in peritoneal dialysis fluid-induced fibrotic peritoneum, as indicated by increased expression of Jagged-1, Notch-1, and HES-1. Blocking Notch signaling activation by intraperitoneal injection of a {gamma}-secretase inhibitor, DAPT, significantly attenuated peritoneal fibrosis as indicated by the decreased expression of {alpha}-smooth muscle actin, collagen I, and vascular endothelial growth factor as well as increased expression of E-cadherin. Moreover, compared with control rats, DAPT-treated rats had a thinner peritoneum with less extracellular matrix accumulation, a lower mass transfer of glucose, and a higher ultrafiltration rate. In addition, transforming growth factor (TGF)-β1 induced Notch signaling activation in primary rat peritoneal mesothelial cells. DAPT blocked this TGF-β1–induced Notch signaling activation and therefore significantly inhibited TGF-β1–induced expression of {alpha}-smooth muscle actin, collagen I, and vascular endothelial growth factor. Thus, a {gamma}-secretase inhibitor that interferes with Notch signaling prevents biochemical, histological, and functional consequences of peritoneal fibrosis through inhibiting epithelial to mesenchymal transition of rat peritoneal mesothelial cells. These results support the use of {gamma}-secretase inhibitors as a novel therapeutic approach for peritoneal fibrosis.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2010 by the American Society for Investigative Pathology.